KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Capital Expenditures (2016 - 2025)

Gilead Sciences (GILD) has disclosed Capital Expenditures for 17 consecutive years, with $205.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 39.46% year-over-year to $205.0 million, compared with a TTM value of $563.0 million through Dec 2025, up 7.65%, and an annual FY2025 reading of $563.0 million, up 7.65% over the prior year.
  • Capital Expenditures was $205.0 million for Q4 2025 at Gilead Sciences, up from $147.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $247.0 million in Q1 2022 and bottomed at $104.0 million in Q1 2025.
  • Average Capital Expenditures over 5 years is $148.9 million, with a median of $142.0 million recorded in 2022.
  • The sharpest move saw Capital Expenditures skyrocketed 49.7% in 2022, then plummeted 55.87% in 2023.
  • Year by year, Capital Expenditures stood at $156.0 million in 2021, then grew by 16.03% to $181.0 million in 2022, then grew by 18.78% to $215.0 million in 2023, then crashed by 31.63% to $147.0 million in 2024, then surged by 39.46% to $205.0 million in 2025.
  • Business Quant data shows Capital Expenditures for GILD at $205.0 million in Q4 2025, $147.0 million in Q3 2025, and $107.0 million in Q2 2025.